Sutro Biopharma (STRO) Announces Proposed Public Offering of 5 Million Shares of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Nasdaq futures lead Wall St higher as Middle East tensions ease
- Tech funds suffer record outflows as investors trim equity positions
- New leader board: Citi refreshes AI compute semiconductor picks
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
December 7, 2020 4:00 PM ESTSOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ --Â Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced a proposed underwritten public offering in which it intends to offer and sell 5,000,000 shares of its common stock. In addition, Sutro intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock offered in the public offering. All of the shares of... More
